ArticleInternational journal of impotence research
Compliance of sildenafil treatment for erectile dysfunction and factors affecting it.
Article in International journal of impotence research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review.International journal of impotence research · 2021Pooled it
- Cost comparison of phosphodiesterase type 5 inhibitors: rural vs urban New York State counties and online pharmacies.Sexual medicine · 2025Article
- Article
- Phenomenological and existential contributions to the study of erectile dysfunction.Medicine, health care, and philosophy · 2021Article
- Can low intensity shockwave therapy match the efficacy of phosphodiesterase-5 inhibitors for erectile dysfunction treatment? A pooled data analysis from two randomized clinical trials.International journal of impotence research · 2021Article
- Different Evaluations Exist between Men with Erectile Dysfunction and Their Female Partners When Using Erectile Hardness Model: An Interesting, Observational, and Cross-Sectional Field Survey.BioMed research international · 2020Article
- Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.Drugs & aging · 2018Review
- Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience.Therapeutic advances in urology · 2016Review
- Erectile Dysfunction Medication Use in Veterans Eligible for Medicare Part D.Journal of managed care & specialty pharmacy · 2016Article
- Erectile dysfunction.Nature reviews. Disease primers · 2016Review
- Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors.PloS one · 2016Observational
- Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction.Pharmacy (Basel, Switzerland) · 2015Article
- Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors?Sexual medicine · 2014Article
- Assessing satisfaction in men and their female partners after treatment with phosphodiesterase type 5 inhibitors for erectile dysfunction.International journal of impotence research · 2013Article
- Improvement in erection hardness and intercourse success with first dose of sildenafil citrate 100 mg.International journal of general medicine · 2013Article
- Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction.Patient preference and adherence · 2008Article
- Results from an online survey investigating ED patients' insights and treatment expectations.International journal of impotence researchArticle
- A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients.International journal of impotence researchArticle
- Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.International journal of impotence researchArticle
- Preference for gender of health care provider in management of erectile dysfunction.International journal of impotence researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the compliance of treatment, its affecting factors, and reasons for dropout, a questionnaire was mailed to a cohort of 2139 subjects who received sildenafil prescriptions for erectile dysfunction (ED) at our institution from 1999 to 2002. A total of 726 subjects (34%) with a mean age of 67 years answered the questionnaires. The response rate for sildenafil treatment was 67%. Of these sildenafil responders, 43% reported that they continued using sildenafil while 57% did not, in a mean follow-up of 3 years. Common reasons for discontinuation were effect below expectations, high cost, loss of interest in sex, and inconvenience in obtaining sildenafil. The continuers showed a higher rate than the discontinuers (P < 0.05) of having tried other treatments, dose titration, and a dose higher than 50 mg. The discontinuers reported having a lower mean responding dose and improvement score post sildenafil treatment than the continuers. In conclusion, effect below expectations was the leading reason for discontinuation of sildenafil treatment. How ED subjects tried the medication and the adequacy of education in the initial treatment period may impact the compliance of sildenafil treatment.
Indexed as
Identifiers
16094412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.